Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biomind LabsBMNDF -41.79%30 3-Year EBITDA Growth Rate is 35.80% as of Mar. 2026, which is 27% below its 10-year median of 49.15. GuruFocus rates BMNDF with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 1,129 Biotechnology companies, Biomind Labs ranks better than 74.22% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 35.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Biomind Labs was 62.50% per year. The lowest was 35.80% per year. And the median was 49.15% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Biomind Labs 3-Year EBITDA Growth Rate Related Terms
BMNDF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Biomind Labs's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomind Labs 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biomind Labs's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Biomind Labs's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 35.80% mean?
Biomind Labs (BMNDF) has a 3-Year EBITDA Growth Rate of 35.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Biomind Labs and its competitors. This is 27% below median its historical median of 49.15. Over the past decade, Biomind Labs' 3-Year EBITDA Growth Rate has ranged from 35.80 to 62.50. According to the industry distribution chart, Biomind Labs ranks #291 out of 1129 companies in the Biotechnology industry, placing it in the top 25.8%.
Is Biomind Labs' 3-Year EBITDA Growth Rate too high?
Biomind Labs' current 3-Year EBITDA Growth Rate of 35.80% is 27% below median its 10-year median of 49.15. Over the past 10 years, this metric has ranged from a low of 35.80 to a high of 62.50. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Biomind Labs' value of 35.80% is 143.5% above this industry median. Based on the distribution chart, Biomind Labs ranks #291 out of 1129 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Biomind Labs has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Biomind Labs' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biomind Labs ranks #291 out of 1129 companies for 3-Year EBITDA Growth Rate. This puts Biomind Labs in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.70. Biomind Labs' value of 35.80% is 143.5% above this benchmark. Historically, Biomind Labs' own 3-Year EBITDA Growth Rate has ranged from 35.80 to 62.50 over the past decade. While the company's 10-year median is 49.15 vs. the industry median of 14.70, Biomind Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biomind Labs's current 3-Year EBITDA Growth Rate of 35.80% is 143.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Biomind Labs and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomind Labs's current 3-Year EBITDA Growth Rate is 35.80%, which is 27% below median its own 10-year median of 49.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomind Labs stock overvalued right now?
Biomind Labs (BMNDF) has a current 3-Year EBITDA Growth Rate of 35.80%. The current 3-Year EBITDA Growth Rate is 35.80%, which is 27% below median its 10-year median of 49.15 and 143.5% above the Biotechnology industry median of 14.70. Biomind Labs' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Biomind Labs (BMNDF), the current 3-Year EBITDA Growth Rate is 35.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biomind Labs Inc is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. The firm is developing pharmaceutical solutions and combined formulations of the main natural psychedelic molecules with the objective of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.
30GF Score
Get the complete analysis for BMNDF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMNDF has been successfully added to your 
